source
- Merck signs $400 million deal with China’s SciBrunch for KRAS G12D preclinical candidateMerck & Co. announced a new partnership with Chinese biotech SciBrunch. The agreement includes a $400 million payment for a preclinical candidate that targets the KRAS G12D mutation. The KRAS G12D…
- Sofinnova Partners raises €82 million to expand medtech creation strategy in Europe and U.S.Sofinnova Partners announced that it has secured €82 million ($93.3 million) in an oversubscribed financing round. The capital will be used to broaden the firm’s medtech creation strategy across Eu…